Catalyst
Slingshot members are tracking this event:
Johnson & Johnson (JNJ) Phase 2 study shows data of Guselkumab versus Humira in treating moderate to severe plaque psoriasis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| JNJ | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Guselkumab, Humira, Plaque Psoriasis
